Breaking Biotech: Absci Leverages AI to Become the GOOGLE of Drug Discovery!
Oct 09, 2021
Sean McClain, founder and CEO of Absci, recently sat down with Breaking Biotech’s Matthew Lepoire to talk about all the exciting things happening with the company. Topics covered included Absci’s bioengineered E. coli strain SoluPro and how recent acquisitions have added drug discovery and AI capabilities to the company’s platform to create an end-to-end solution that can help drug development companies streamline their preclinical and clinical programs.
Listen to the full interview here: